| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole manufacturers
- GSK3β inhibitor II
-
-
2026-07-10
- CAS:478482-75-6
- Min. Order: 1KG
- Purity: 98%
- Supply Ability: 20Tons
|
| | 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole Basic information |
| Product Name: | 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole | | Synonyms: | TIBPO;GLYCOGEN SYNTHASE KINASE-3 INHIBITOR II;GSK-3 INHIBITOR II;Pyridine, 4-[5-[[(3-iodophenyl)Methyl]thio]-1,3,4-oxadiazol-2-yl]-;4-[5-[[(3-Iodophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]pyridine;GSK3.beta. Inhibitor II;GSK-3β Inhibitor II - CAS 478482-75-6 - Calbiochem;GSK3β Inhibitor II | | CAS: | 478482-75-6 | | MF: | C14H10IN3OS | | MW: | 395.22 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole Structure](StructureFile/ChemBookStructure7/GIF/CB2201711.gif) |
| | 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole Chemical Properties |
| Boiling point | 532.6±60.0 °C(Predicted) | | density | 1.79±0.1 g/cm3(Predicted) | | storage temp. | -20C | | solubility | ≤3mg/ml in DMSO;10mg/ml in dimethyl formamide | | form | Yellow solid | | pka | 0.97±0.10(Predicted) | | color | White to off-white |
| | 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole Usage And Synthesis |
| Uses | GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD)[1]. | | Definition | ChEBI: 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole is an aryl sulfide. | | Biological Activity | gsk-3β inhibitor ii is a gsk-3β inhibitor.glycogen synthase kinase-3 (gsk-3), a protein-serine kinase, is implicated in the hormonal control of various regulatory proteins. a number of substrates have been identified, which implicates gsk-3 in the regulation of several physiological processes. moreover, it has been reported that compounds that specifically inhibit gsk-3 activity may be useful in the treatment of diabetes. | | in vitro | in a previous study, by using a virtual screening strategy based on a methodology derived from the cats molecular descriptor, a novel compound class including gsk-3β inhibitor ii with inhibitory activity against the gsk-3 enzyme was identified via scaffold hopping. gsk-3β inhibitor ii was found to be a potent inhibitor of gsk-3β with the ic50 value of 390 nm. however, gsk-3β inhibitor ii was not able to inhibit another gsk-3 isoform, gsk-3α [1]. another study found that gsk-3β inhibitor ii could block the functional regulation of p53 through inhibiting gsk-3β, decreasing mdm2 levels, and modulating mitochondrial p53 apoptotic signaling [2]. | | IC 50 | 390 nm for gsk-3β | | references | [1] naerum, l. ,nrskov-lauritsen, l. and olesen, p.h. scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. bioorg.med.chem.lett. 12(11), 1525-1528 (2002). [2] watcharasit, p. ,bijur, g.n.,song, l., et al. glycogen synthase kinase-3beta (gsk3beta) binds to and promotes the actions of p53. j.biol.chem. 278(49), 49972-48879 (2003). |
| | 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole Preparation Products And Raw materials |
|